Abstract
The discovery of bacterial viruses approximately 100 years ago fairly quickly led to their use as antibacterial agents. For roughly two decades – early 1920s to early 1940s – bacteriophages represented the only means readily available to medicine by which many bacterial infections might be treated and cured. This near monopoly, however, came to a close as antibiotics became generally available. Antibiotics, especially as more broadly specific, selectively toxic antibacterials were both more easily developed and more easily used medicinals than phages. Phage therapy did not disappear from medical practice altogether, however, and increasingly is viewed as a viable alternative to antibiotics under circumstances where bacterial resistance to antibiotics is an issue. In addition are circumstances where a more selectively toxic antibacterial is desired, antibacterials that, for example, have less of a negative impact on nontarget members of a body’s microbiome. As for any drug, the successful development of phage therapeutics requires a pharmacological approach, whether implicit or, ideally, explicitly implemented. In this chapter, we consider pharmacokinetic and pharmacodynamic principles, body impact on drugs and drug impact on body, respectively, and both as they may be applied to the development of phage-based antimicrobials. As an important facet of both the pharmacokinetics and pharmacodynamics of phage therapy, we take a close look particularly at phage interactions with the mammalian immune system.
Similar content being viewed by others
References
Abedon ST (2008) Phage, bacteria, and food. Appendix: rate of adsorption is function of phage density. In: Abedon ST (ed) Bacteriophage ecology. Cambridge University Press, Cambridge, UK, pp 321–324
Abedon ST (2009) Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis 6:807–815
Abedon ST (2010) The ‘nuts and bolts’ of phage therapy. Curr Pharm Biotechnol 11:1
Abedon S (2011a) Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol 77:1–40
Abedon ST (2011b) Bacteriophages and biofilms: ecology, phage therapy, plaques. Nova Science Publishers, Hauppauge
Abedon ST (2011c) Envisaging bacteria as phage targets. Bacteriophage 1:228–230
Abedon ST (2011d) Lysis from without. Bacteriophage 1:46–49
Abedon ST (2012a) Bacterial ‘immunity’ against bacteriophages. Bacteriophage 2:50–54
Abedon ST (2012b) Phage therapy best practices. In: Hyman P, Abedon ST (eds) Bacteriophages in health and disease. CABI Press, Wallingford, pp 256–272
Abedon ST (2012c) Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities. Viruses 4:663–687
Abedon ST (2014a) Bacteriophages as drugs: the pharmacology of phage therapy. In: Borysowski J, Międzybrodzki R, Górski A (eds) Phage therapy: current research and applications. Caister Academic Press, Norfolk, pp 69–100
Abedon ST (2014b) Phage therapy: eco-physiological pharmacology. Scientifica 2014:581639
Abedon ST (2015a) Bacteriophage secondary infection. Virol Sin 30:3–10
Abedon ST (2015b) Ecology of anti-biofilm agents I. Antibiotics versus bacteriophages. Pharmaceuticals 8:525–558
Abedon ST (2015c) Ecology of anti-biofilm agents II. Bacteriophage exploitation and biocontrol of biofilm bacteria. Pharmaceuticals 8:559–589
Abedon ST (2015d) Phage therapy of pulmonary infections. Bacteriophage 5:e1020260
Abedon ST (2016a) Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets? FEMS Microbiol Lett 363:fnv246
Abedon ST (2016b) Phage therapy dosing: the problem(s) with multiplicity of infection (MOI). Bacteriophage 6:e1220348
Abedon ST (2017a) Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes. AIMS Microbiol 3:649–688
Abedon ST (2017b) Bacteriophage clinical use as antibactertial “drugs”: utility precident. Microbiol Spectr 5: BAD-0003-2016
Abedon ST (2017c) Information phage therapy research should report. Pharmaceuticals (Basel) 10:43
Abedon ST (2017d) Phage “delay” towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages. AIMS Microbiol 3:186–226
Abedon ST (2018a) Bacteriophage-mediated biocontrol of wound infections, and ecological exploitation of biofilms by phages. In: Shiffman M (ed) Recent clinical techniques, results, and research in wounds. Springer
Abedon ST (2018b) Phage therapy: various perspectives on how to improve the art. In: Medina C, López-Baena F (eds) Host-pathogen interactions. Humana Press, New York, pp 113–127
Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11:28–47
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1:66–85
Ackermann H-W (2005) Bacteriophage classification. In: Kutter E, Sulakvelidze A (eds) Bacteriophages: biology and application. CRC Press, Boca Raton, pp 67–90
Aronow R, Danon D, Shahar A, Aronson M (1964) Electron microscopy of in vitro endocytosis of T2 phage by cells from rabbit peritoneal exudate. J Exp Med 120:943–954
Barr JJ (2017) A bacteriophages journey through the human body. Immunol Rev 279:106–122
Boratyński J, Syper D, Weber-Dąbrowska B, Łusiak-Szelachowska M, Poźniak G, Górski A (2004) Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9:253–259
Borysowski J, Międzybrodzki R, Górski A (2014) Phage therapy: current research and applications. Caister Academic Press, Norfolk
Brussow H (2013) Bacteriophage-host interaction: from splendid isolation into a messy reality. Curr Opin Microbiol 16:500–506
Bruttin A, Brüssow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874–2878
Bryan D, El-Shibiny A, Hobbs Z, Porter J, Kutter EM (2016) Bacteriophage T4 infection of stationary phase E. coli: life after log from a phage perspective. Front Microbiol 7:1391
Bull JJ, Gill JJ (2014) The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front Microbiol 5:618
Bull JJ, Regoes RR (2006) Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc R Soc Lond B Biol Sci 273:2703–2712
Campbell AM (2006) General aspects of lysogeny. In: Calendar R, Abedon ST (eds) The bacteriophages. Oxford University Press, Oxford, pp 66–73
Carlton RM (1999) Phage therapy: past history and future prospects. Arch Immunol Ther Exp 47:267–274
Casjens SR, Hendrix RW (2015) Bacteriophage lambda: early pioneer and still relevant. Virology 479–480:310–330
Chan BK, Abedon ST (2012a) Bacteriophage adaptation, with particular attention to issues of phage host range. In: Quiberoni A, Reinheimer J (eds) Bacteriophages in dairy processing. Nova Science Publishers, Hauppauge, pp 25–52
Chan BK, Abedon ST (2012b) Phage therapy pharmacology: phage cocktails. Adv Appl Microbiol 78:1–23
Chan BK, Abedon ST (2015) Bacteriophages and their enzymes in biofilm control. Curr Pharm Des 21:85–99
Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783
Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D (2018) Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 1:60–66
Chanishvili N (2012a) A literature review of the practical application of bacteriophage research. Nova Science Publishers, Hauppauge
Chanishvili N (2012b) Phage therapy – history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res 83:3–40
Christie GE, Allison HA, Kuzio J, McShan M, Waldor MK, Kropinski AM (2012) Prophage-induced changes in cellular cytochemistry and virulence. In: Hyman P, Abedon ST (eds) Bacteriophages in health and disease. CABI Press, Wallingford, pp 33–60
Curtright AJ, Abedon ST (2011) Phage therapy: emergent property pharmacology. J Bioanal Biomed S3:010
Dąbrowska K, Miernikiewicz P, Piotrowicz A, Hodyra K, Owczarek B, Lecion D, Kaźmierczak Z, Letarov A, Górski A (2014) Immunogenicity studies of proteins forming the T4 phage head surface. J Virol 88:12551–12557
Dy RL, Richter C, Salmond GP, Fineran PC (2014) Remarkable mechanisms in microbes to resist phage infections. Annu Rev Virol 1:307–331
Fan X, Li W, Zheng F, Xie J (2013) Bacteriophage inspired antibiotics discovery against infection involved biofilm. Crit Rev Eukaryot Gene Expr 23:317–326
Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S (2016) Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 25(Suppl 7):S27–S33
Fogelman I, Davey V, Ochs HD, Elashoff M, Feinberg MB, Mican J, Siegel JP, Sneller M, Lane HC (2000) Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 182:435–441
Geier MR, Trigg ME, Merril CR (1973) The fate of bacteriophage lambda in non-immune germ-free mice. Nature (London) 246:221–223
Gill JJ, Hyman P (2010) Phage choice, isolation and preparation for phage therapy. Curr Pharm Biotechnol 11:2–14
Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11:15–27
Górski A, Weber-Dąbrowska B (2005) The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62:511–519
Górski A, Kniotek M, Perkowska-Ptasinska A, Mroz A, Przerwa A, Gorczyca W, Dąbrowska K, Weber-Dąbrowska B, Nowaczyk M (2006a) Bacteriophages and transplantation tolerance. Transplant Proc 38:331–333
Górski A, Wazna E, Dąbrowska B-W, Switala-Jelén K, Międzybrodzki R (2006b) Bacteriophage translocation. FEMS Immunol Med Microbiol 46:313–319
Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołas A, Purchla S, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogóz P, Kłosowska D (2012) Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83:41–71
Górski A, Dąbrowska K, Hodyra-Stefaniak K, Borysowski J, Międzybrodzki R, Weber-Dąbrowska B (2015) Phages targeting infected tissues: novel approach to phage therapy. Future Microbiol 10:199–204
Gutíerrez D, Rodríguez-Rubio L, Martínez B, Rodríguez A, García P (2016) Bacteriophages as weapons against bacterial biofilms in the food industry. Front Microbiol 7:825
Hagens S, Loessner MJ (2010) Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 11:58–68
Hajek P (1967) Properties of natural 19S antibodies in normal pig serum against the FX174 and T2 phages. Folia Microbiol 12:551–556
Harper DR, Morales S (2012) Bacteriophage therapy: practicability and clinical need meet in the multidrug-resistance era. Future Microbiol 7:797–799
Harper DR, Parracho HMR, Walker J, Sharp R, Hughes G, Werthrén M, Lehman S, Morales S (2014) Bacteriophages and biofilms. Antibiotics 3:270–284
Henry M, Lavigne R, Debarbieux L (2013) Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 57:5961–5968
Hobbs Z, Abedon ST (2016) Diversity of phage infection types and associated terminology: the problem with ‘Lytic or lysogenic’. FEMS Microbiol Lett 363:fnw047
Hodyra-Stefaniak K, Miernikiewicz P, Drapala J, Drab M, Jończyk-Matysiak E, Lecion D, Kaźmierczak Z, Beta W, Majewska J, Harhala M, Bubak B, Kłopot A, Górski A, Dąbrowska K (2015) Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep 5:14802
Huff WE, Huff GR, Rath NC, Donoghue AM (2010) Immune interference of bacteriophage efficacy when treating colibacillosis in poultry. Poult Sci 89:895–900
Hyman P, Abedon ST (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217–248
Hyman P, Abedon ST (2012) Bacteriophages in health and disease. CABI Press, Wallingford
Inchley CJ (1969) The activity of mouse Kuppfer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol 5:173–187
Janeway CA, Travers P, Walport M, Shlomchik MJ (2005) Immunology. Garland Science, New York
Jończyk-Matysiak E, Łusiak-Szelachowska M, Kłak M, Bubak B, Międzybrodzki R, Weber-Dąbrowska B, Żaczek M, Fortuna W, Rogóz P, Letkiewicz S, Szufnarowski K, Gorski A (2015) The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J Immunol Res 2015:482863
Kantoch M (1958) Studies on phagocytosis of bacterial viruses. Arch Immunol Ther Exp 6:63–84
Kantoch M (1961) The role of phagocytes in virus infections. Arch Immunol Ther Exp 9:261–340
Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat Immunol 7:131–137
Khalifa L, Shlezinger M, Beyth S, Houri-Haddad Y, Coppenhagen-Glazer S, Beyth N, Hazan R (2016) Phage therapy against Enterococcus faecalis in dental root canals. J Oral Microbiol 8:32157
Kucharewicz-Krukowska A, Slopek S (1987) Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp 35:553–561
Kuhl S, Hyman P, Abedon ST (2012) Diseases caused by phages. In: Hyman P, Abedon ST (eds) Bacteriophages in health and disease. CABI Press, Wallingford, pp 21–32
Kumari S, Harjai K, Chhibber S (2010) Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice. J Microbiol Biotechnol 20:935–941
Kutateladze M, Adamia R (2008) Phage therapy experience at the Eliava institute. Med Mal Infect 38:426–430
Kutter E, Sulakvelidze A (2005) Bacteriophages: biology and application. CRC Press, Boca Raton
Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69–86
Kutter E, Borysowski J, Międzybrodzki R, Górski A, Weber-Dąbrowska B, Kutateladze M, Alavidze Z, Goderdzishvili M, Adamia R (2014) Clinical phage therapy. In: Borysowski J, Międzybrodzki R, Górski A (eds) Phage therapy: current research and applications. Caister Academic Press, Norfolk, pp 257–288
Kutter EM, Kuhl SJ, Abedon ST (2015) Re-establishing a place for phage therapy in western medicine. Future Microbiol 10:685–688
Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327
Langbeheim H, Teitelbaum D, Arnon R (1978) Cellular immune response toward MS-2 phage and a synthetic fragment of its coat protein. Cell Immunol 38:193–197
Letarov AV, Golomidova AK, Tarasyan KK (2010) Ecological basis of rational phage therapy. Acta Nat 2:60–71
Lindberg HM, McKean KA, Wang I-N (2014) Phage fitness may help predict phage therapy efficacy. Bacteriophage 4:e964081
Łobocka M, Hejnowicz MS, Gagala U, Weber-Dąbrowska B, Wegrzyn G, Dadlez M (2014) The first step to bacteriophage therapy: how to choose the correct phage. In: Borysowski J, Międzybrodzki R, Górski A (eds) Phage therapy: current research and applications. Caister Academic Press, Norfolk, pp 23–67
Łusiak-Szelachowska M, Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, Kłak M, Fortuna W, Letkiewicz S, Rogóz P, Szufnarowski K, Jończyk-Matysiak E, Owczarek B, Górski A (2014) Phage neutralization by sera of patients receiving phage therapy. Viral Immunol 27:295–304
Majewska J, Beta W, Lecion D, Hodyra-Stefaniak K, Klopot A, Kazmierczak Z, Miernikiewicz P, Piotrowicz A, Ciekot J, Owczarek B, Kopciuch A, Wojtyna K, Harhala M, Mąkosa M, Dąbrowska K (2015) Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7:4783–4799
McCallin S, Alam SS, Barretto C, Sultana S, Berger B, Huq S, Krause L, Bibiloni R, Schmitt B, Reuteler G, Brüssow H (2013) Safety analysis of a Russian phage cocktail: from metaGenomic analysis to oral application in healthy human subjects. Virology 443:187–196
Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature (London) 449:819–826
Merril CR (2008) Interaction of bacteriophages with animals. In: Abedon ST (ed) Bacteriophage ecology. Cambridge University Press, Cambridge, UK, pp 332–352
Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188–3192
Miedzybrodzki R, Switala-Jelen K, Fortuna W, Weber-Dabrowska B, Przerwa A, Lusiak-Szelachowska M, Dabrowska K, Kurzepa A, Boratynski J, Syper D, Pozniak G, Lugowski C, Górski A (2008) Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res 131:233–242
Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A (2009) A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med 9:303–312
Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawełczyk Z, Rogóz P, Kłak M, Wojtasik E, Górski A (2012) Clinical aspects of phage therapy. Adv Virus Res 83:73–121
Miernikiewicz P, Dąbrowska K, Piotrowicz A, Owczarek B, Wojas-Turek J, Kicielińska J, Rossowska J, Pajtasz-Piasecka E, Hodyra K, Macegoniuk K, Rzewucka K, Kopciuch A, Majka T, Letarov A, Kulikov E, Maciejewski H, Górski A (2013) T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS One 8:e71036
Miernikiewicz P, Klopot A, Soluch R, Szkuta P, Kęska W, Hodyra-Stefaniak K, Konopka A, Nowak M, Lecion D, Kaźmierczak Z, Majewska J, Harhala M, Gorski A, Dąbrowska K (2016) T4 phage tail adhesin gp12 counteracts LPS-induced inflammation in vivo. Front Microbiol 7:1112
Motlagh AM, Bhattacharjee AS, Goel R (2016) Biofilm control with natural and genetically-modified phages. World J Microbiol Biotechnol 32:67
Muckenfuss RS (1928) Studies on the bacteriophage of d’Hérelle. XI. An inquiry into the mode of action of antibacteriophage serum. J Exp Med 48:709–722
Mushtaq N, Redpath MB, Luzio JP, Taylor PW (2004) Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob Agents Chemother 48:1503–1508
Nguyen S, Baker K, Padman BS, Patwa R, Dunstan RA, Weston TA, Schlosser K, Bailey B, Lithgow T, Lazarou M, Luque A, Rohwer F, Blumberg RS, Barr JJ (2017) Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. MBio 8:e01874
Olszowska-Zaremba N, Borysowski J, Dąbrowska K, Górski A (2012) Phage translocation, safety, and immunomodulation. In: Hyman P, Abedon ST (eds) Bacteriophages in health and disease. CABI Press, Wallingford, pp 168–184
Pancer Z, Cooper MD (2006) The evolution of adaptive immunity. Annu Rev Immunol 24:497–518
Parasion S, Kwiatek M, Gryko R, Mizak L, Malm A (2014) Bacteriophages as an alternative strategy for fighting biofilm development. Pol J Microbiol 63:137–145
Park K, Cha KE, Myung H (2014) Observation of inflammatory responses in mice orally fed with bacteriophage T7. J Appl Microbiol 117:627–633
Payne RJH, Jansen VAA (2001) Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 208:37–48
Payne RJH, Phil D, Jansen VAA (2000) Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 68:225–230
Payne RJH, Jansen VAA (2003) Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 42:315–325
Perreau M, Guerin MC, Drouet C, Kremer EJ (2007) Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer. Mol Ther 15:1998–2007
Pincus NB, Reckhow JD, Saleem D, Jammeh ML, Datta SK, Myles IA (2015) Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS One 10:e0124280
Pirnay JP, De VD, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R (2011) The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res 28:934–937
Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De VD, Gabard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Vaneechoutte M, Van PL, Verbeken G, Zizi M, Van den Eede G (2015) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173–2179
Przybylski M, Borysowski J, Jakubowska-Zahorska R, Weber-Dąbrowska B, Górski A (2015) T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro. Future Microbiol 10:453–460
Rus H, Cudrici C, Niculescu F (2005) The role of the complement system in innate immunity. Immunol Res 33:103–112
Ryan EM, Gorman SP, Donnelly RF, Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63:1253–1264
Sabour PM, Griffiths MW (2010) Bacteriophages in the control of food and, waterborne pathogens. ASM Press, Washington, DC
Schmerer M, Molineux IJ, Bull JJ (2014) Synergy as a rationale for phage therapy using phage cocktails. PeerJ 2:e590
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954-17
Seed KD (2015) Battling phages: how bacteria defend against viral attack. PLoS Pathog 11:e1004847
Sillankorva S, Azeredo J (2014) The use of bacteriophages and bacteriophage-derived enzymes for clinically relevant biofilm control. In: Borysowski J, Międzybrodzki R, Górski A (eds) Phage therapy: current research and applications. Caister Academic Press, Norfolk
Smith HW, Huggins MB, Shaw KM (1987) Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Microbiol 133:1127–1135
Sokoloff AV, Bock I, Zhang G, Sebestyen MG, Wolff JA (2000) The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. Mol Ther 2:131–139
Speck P, Smithyman A (2016) Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 363:fnv242
Srivastava AS, Kaido T, Carrier E (2004) Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods 115:99–104
Stent GS (1963) Molecular Biology of Bacterial Viruses. WH Freeman and Co., San Francisco, CA
Sulakvelidze A, Kutter E (2005) Bacteriophage therapy in humans. In: Kutter E, Sulakvelidze A (eds) Bacteriophages: biology and application. CRC Press, Boca Raton, pp 381–436
Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649–659
Summers WC (2005) History of phage research and phage therapy. In: Waldor M, Friedman D, Adhya S (eds) Phages: their role in bacterial pathogenesis and biotechnology. ASM Press, Washington, DC
Summers WC (2012) The strange history of phage therapy. Bacteriophage 2:130–133
Szermer-Olearnik B, Boratyński J (2015) Removal of endotoxins from bacteriophage preparations by extraction with organic solvents. PLoS One 10:e0122672
Uchiyama J, Maeda Y, Takemura I, Chess-Williams R, Wakiguchi H, Matsuzaki S (2009) Blood kinetics of four intraperitoneally administered therapeutic candidate bacteriophages in healthy and neutropenic mice. Microbiol Immunol 53:301–304
Wei W, Krone SM (2005) Spatial invasion by a mutant pathogen. J Theor Biol 236:335–348
Zimecki M, Artym J, Kocięba M, Weber-Dąbrowska B, Borysowski J, Górski A (2009) Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. BMC Microbiol 9:169
Acknowledgments
KD’s work was supported by National Science Centre in Poland, grant UMO-2012/05/E/NZ6/03314.
AG’s work was supported by National Science Centre in Poland, grant DEC-2013/11/B/NZ1/02107.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Dąbrowska, K., Górski, A., Abedon, S.T. (2018). Bacteriophage Pharmacology and Immunology. In: Harper, D., Abedon, S., Burrowes, B., McConville, M. (eds) Bacteriophages. Springer, Cham. https://doi.org/10.1007/978-3-319-40598-8_9-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-40598-8_9-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40598-8
Online ISBN: 978-3-319-40598-8
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences